Pfizer’s Trazimera (trastuzumab-biosimilar) Receives FDA’s Approval for HER-2+ Breast Cancer and m-Gastric/GEJ Cancer

 Pfizer’s Trazimera (trastuzumab-biosimilar) Receives FDA’s Approval for HER-2+ Breast Cancer and m-Gastric/GEJ Cancer

Pfizer’s Trazimera (trastuzumab-biosimilar) Receives FDA’s Approval for HER-2+ Breast Cancer and m-Gastric/GEJ Cancer

Shots:

  • The approval is based on REFLECTIONS B327-02 study assessing Trazimera in 500 patients with HER2 overexpressing breast cancer & m- gastric/GEJ adenocarcinoma across 20 countries
  • REFLECTIONS B327-02 study demonstrated a high degree of similarity & no clinical differences b/w Trazimera & Herceptin
  • Trazimera (trastuzumab-biosimilar) is a HER2 receptor antagonist biosimilar to Herceptin and has received EU’s approval in Jul’18 for the same indication

Click here to read full press release/ article | Ref: Pfizer | Image: Pfizer Centreone

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post